Background and aims
Several preclinical studies have shown that spinal cord stimulation (SCS) reduces sympathetic activation, reverses adverse cardiac remodelling, improves pump function, and suppresses ventricular arrhythmias in animal models of heart failure (HF) with reduced ejection fraction and suppresses ventricular arrhythmias in animal models of HF with reduced ejection fraction. 1 -4 However, the mechanism of SCS benefit in experimental HF remains poorly defined, and data on SCS in patients with HF is limited. Several biomarkers reflect pivotal aspects of HF pathophysiology and severity (e.g. neurohormonal activation, inflammation and cytokine triggering), and cardiac injury and stress. The effect of SCS on these biomarkers in patients with chronic HF remains largely unknown.
Therefore, the objective of the present study was to test the hypothesis that SCS improves levels of neurohormones, inflammatory markers and cytokines and that this is paralleled by a reduction in biomarkers reflecting cardiac stress and injury.
Methods
Patients were recruited from Na Homolce Hospital, Prague, Czech Republic, and Karolinska University Hospital, Stockholm, Sweden. The present study was a substudy to the DEFEAT-HF clinical trial. 5 Inclusion criteria were enrolment in the main trial for ≥12 months with adequate battery life remaining on the implanted neurostimulator and being willing and able to participate in the study. chamber dilatation, and on optimal medical therapy. Main exclusion criteria were cardiac resynchronization therapy treatment, recent acute coronary syndrome and uncorrected severe mitral regurgitation. All patients included had completed the 12-month and final study visit in the DEFEAT-HF trial. Therefore, all study subjects had received at least 6-12 months of SCS before inclusion in the present study and were programmed to SCS-ON when arriving for the baseline visit. This study was a randomized, controlled, investigator-blind crossover study where SCS was either turned off (SCS-OFF) for 6 weeks followed by 6 weeks on (SCS-ON), or vice versa.
Patients had been implanted with a single lead with eight electrodes (Model 3777/3877, Medtronic Plc, Minneapolis, MN, USA) targeting the T2-T4 level of the spinal cord. The lead was tunnelled subcutaneously and connected to a PrimeADVANCED™ neurostimulator (Model 37002, Medtronic Plc) surgically implanted in the abdominal region. During the SCS-ON intervention, the stimulator was programmed to stimulate for 12 h/day at 50 Hz with a 0.21 ms pulse duration at an amplitude corresponding to 90% of the maximal voltage tolerated by the patient. This mode of SCS delivery was identical, as in the main DEFEAT-HF study.
The regional ethics review board at both participating institutions approved the protocol and all study subjects provided written informed consent to participate in the study. The investigation conformed with the principles outlined in the Declaration of Helsinki.
At baseline, and the 6-and 12-week visits, peripheral venous blood and saliva samples were collected from the study subjects after at least 15 min of supine rest. Patients were instructed to be fasting and abstain from caffeinated beverages for at least 12 h before each study visit. Blood and saliva samples were handled according to clinical routine and analysed at the Department of Clinical Chemistry at Karolinska University Hospital.
Comparisons of blood and saliva biomarker levels collected after SCS-ON and SCS-OFF were performed using a Wilcoxon signedrank test. Pearson correlation coefficients were used to estimate any associations between SCS-associated change in high sensitivity troponin T (hs-TnT) and change in other biomarkers. All statistical analyses were performed using SAS (Ver 9. 
Results
The baseline characteristics and biomarker levels of the 13 study patients are presented in Table 1 . Mean age was 65 ± 8 years and 69% of study subjects were male. Background treatment with evidence based drugs and devices was high. Average LVEF was 43 ± 14%, which was significantly (P = 0.007) higher compared with when patients were included in the main DEFEAT-HF trial 26 ± 8 months earlier (31 ± 5%). Ten patients were in NYHA functional class II and the remaining three were in NYHA class III. Hence, NYHA class had improved significantly (P < 0.001) compared with that at inclusion in the DEFEAT-HF trial, when all patients were in NYHA class III. There were nine patients from Na Homolce Hospital, Prague, Czech Republic, and four from Karolinska University Hospital, Stockholm, Sweden.
The level of hs-TnT was modestly but significantly higher during SCS-ON compared with SCS-OFF, which may reflect cardiac injury (Figure 1a) . This sign of possible adverse effect of SCS was observed regardless of randomization arm (Figure 1b . Figure 1c -f shows the effect of SCS on biomarkers of inflammation and cytokine activation. The use of SCS was not associated with increase in high sensitivity C-reactive protein (SCS-ON 3.6 ± 4.5 mg/L vs. SCS-OFF 3.6 ± 4.9 mg/L, P = 0.39). There was a trend towards increased interleukin-1 (IL-1) and interleukin-6 (IL-6) with SCS although it did not reach statistical significance (P = 0.08 and P = 0.09, respectively) when comparing SCS-OFF and SCS-ON. There was no significant correlation between change in hs-TnT and change in either IL-1 (r = 0.06, P = 0.83) or IL-6 (r = -0.42, P = 0.15) with SCS applied compared with turned off. Tumour 
58 ± 115 IL-6, pg/mL (<7) 21 ± 34 TNF-, pg/mL (<12) 22 ± 21 Saliva-cortisol, μg/dL (≤1. 6) 0.7 ± 0.5
All continuous variables are presented as mean ± standard deviation except NT-proBNP, which is presented as median [interquartile range]. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; hsCRP, high-sensitivity Creactive protein; hs-TnT, high-sensitivity troponin T; ICD, implantable cardioverter defibrillator; IL-1, interleukin-1; IL-6, interleukin-6; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; NTproBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; TNF-, tumour necrosis factor alpha.
necrosis factor (TNF)-was unchanged comparing SCS-ON (27 ± 33 pg/mL) and SCS-OFF (22 ± 21 pg/mL, P = 0.20). Saliva levels of cortisol did not change significantly with SCS-ON. It was found that SCS-ON did not have a significant impact on venous blood concentrations of noradrenaline, renin, and aldosterone (Figure 1g-i) .
Discussion
In the present study we investigated the effect of SCS, delivered for 12 h/day, aimed at the T2-T4 segment of the spinal cord, on disease-associated biomarkers in patients with chronic moderately severe HF. We found a small but significant increase in hs-TnT, which may indicate cardiac injury, especially as renal function was unchanged. The modest increase in hs-TnT is not likely to be clinically relevant per se but may indicate a possible adverse cardiac effect of SCS in humans with HF that warrants further investigations as to its mechanism and significance. Notably, a recent study suggests that even minor changes in multiple individual biomarkers (including hs-TnT) may signal increased risk for adverse outcome in patients with HF. 6 The increase in hs-TnT was paralleled by a trend towards an increase in cytokine activation associated with SCS. In this small study, we could not find a strong association between the level of cytokine activation and cardiac injury measured with hs-TnT. Both IL-1 and IL-6 are pro-inflammatory cytokines produced by cells in the heart 7 in response to cardiac insult 8 and have been associated with reverse remodelling and HF development/worsening. 8 Use of SCS had a neutral effect on both sympathetic nervous system activation and the renin-angiotensin-aldosterone axis when assessed by levels of circulating hormones.
. .................................................................................................................................................................................................................. Taken together, the data from this study suggest a potential deleterious effect of SCS in patients with HF that may be mediated through cytokine activation and result in myocyte injury.
Unlike in the main DEFEAT-HF trial, the present study did not evaluate clinical or echocardiographic variables of the patients but the absence of improvement, and any signalling of harm in the biomarker profile change associated with SCS in this study contrasts with previous experimental studies in animal models of HF and with the small clinical SCS HEART study that documented several beneficial effects of SCS. 2 -4,9 In contrast, the main DEFEAT-HF trial was neutral in terms of the effect of SCS on reverse remodelling, quality of life, and exercise capacity. 5 The present study suggests that cytokine activation and myocyte injury may have contributed to the lack of benefit of SCS in the DEFEAT-HF trial.
Importantly, there are differences in therapy delivery between the present study and the DEFEAT-HF trial on one hand, and experimental animal studies and the SCS HEART study on the other. Differences include stimulation amplitude and hours/day with therapy delivery as well as spinal cord segment stimulated and lead/electrode number and stimulation mode. Whether therapy delivery can be modified and thereby improved compared with what was used in this study warrants further investigations.
Conclusion
In patients with HF, SCS delivered at the T2-T4 segment for 12 h/day was associated with a modest but significant increase in hs-TnT, which may reflect cardiac injury. This was paralleled by a trend towards elevated levels of circulating cytokines. The small magnitude of the hs-TnT increase is not likely to be clinically relevant but the findings from this study may imply a novel mechanism regarding SCS in HF: myocyte injury with associated cytokine release. 
